DIRS.INFO The most relevant business & tech news

☆ Oppenheimer's top stock picks heading into year-end
▼ + stars: | 2024-11-20 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Meanwhile, the Dow Jones Industrial Average and the S & P 500 are each up more than 3% month to date. As November nears its close, Oppenheimer has updated its top stock ideas list. Its $145 price target reflects almost 22% upside from Tuesday's close. Oppenheimer believes medical technology company Transmedics is also due for a rally, as its $125 target reflects nearly 51% upside from Tuesday's close. TMDX YTD mountain TMDX, year-to-date For newly added Citigroup, Oppenheimer's $107 target implies more than 56% upside from Tuesday's close.

Persons: Stocks, Donald Trump's, Oppenheimer, Rob Lynch, Brian Bittner, Suraj Kalia Organizations: Oppenheimer, Nasdaq, Dow Jones Industrial, Citigroup, Oppenheimer's Locations: Instacart

☆ Oppenheimer's Owen Lau on why crypto will benefit from Trump 2.0
▼ + stars: | 2024-11-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailOppenheimer's Owen Lau on why crypto will benefit from Trump 2.0Owen Lau, senior analyst at Oppenheimer, joins CNBC's 'The Exchange' to discuss how crypto is set up from here, how president-elect Trump's SEC pick could impact the space, and more.

Persons: Oppenheimer's Owen Lau, Owen Lau, Oppenheimer Organizations: Trump, Trump's SEC

☆ What Wall Street expects from Amazon, Apple earnings after the bell
▼ + stars: | 2024-10-31 | by ( Samantha Subin | ) www.cnbc.com time to read: +6 min

Wall Street faces another key litmus test Thursday with results from megacap technology giants Apple and Amazon . For Apple, Wall Street also wants to see its latest iPhone pick up steam, and investors seek more insight into when the company's AI initiative will begin lifting sales. For Apple, Wall Street expects EPS of $1.60 on $94.58 billion in revenue. Amazon's retail business also remains top of mind for Wall Street ahead of the busy holding shopping period. Apple For Apple, Wall Street is eagerly searching for signs of strong demand for its latest iPhone model and updates on its AI strategy.

Persons: Jason Helfstein, Brent Thill, Bank of America's Justin Post, Doug Anmuth, Goldman Sachs, Eric Sheridan, Ronald Josey, Morgan Stanley, Erik Woodring, Jefferies, Edison Lee, Samik Chatterjee, Davidson's Gil Luria, Wamsi Mohan, Tim Long, AAPL, Long Organizations: Apple, Nasdaq, Microsoft, Wall, LSEG, Amazon, StreetAccount, Jefferies, Bank of America's, Apple Intelligence, " Bank of America, Barclays Locations: Amazon

☆ Alphabet is not a 'favored' name among investors right now, says Oppenheimer's Jason Helfstein
▼ + stars: | 2024-10-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAlphabet is not a 'favored' name among investors right now, says Oppenheimer's Jason HelfsteinJason Helfstein, Oppenheimer analyst, joins 'Squawk on the Street' to discuss what Helfstein is looking for Alphabet to say about its spending on AI, the biggest headwind for Alphabet, and much more.

Persons: Jason Helfstein Jason Helfstein, Oppenheimer

☆ Meta technicals show stock has room to run, says Oppenheimer's Ari Wald
▼ + stars: | 2024-10-28 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMeta technicals show stock has room to run, says Oppenheimer's Ari WaldAri Wald, head of technical analysis at Oppenheimer, joins CNBC's 'The Exchange' to discuss expectations for Meta ahead of earnings, technicals supporting the valuation, and more.

Persons: Oppenheimer's Ari Wald Ari Wald, Oppenheimer Organizations: Meta

☆ Tesla doesn't need a low-end vehicle to continue to grow, says Oppenheimer's Colin Rusch
▼ + stars: | 2024-10-28 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTesla doesn't need a low-end vehicle to continue to grow, says Oppenheimer's Colin RuschColin Rusch, Oppenheimer senior research analyst, joins 'Squawk Box' to discuss Tesla's quarterly results and post earnings surge, what's next for the EV maker, Tesla's autonomous driving ambitions, competition from China, and more.

Persons: Colin Rusch Colin Rusch, Oppenheimer Locations: China

☆ Here are Oppenheimer's best stock ideas heading into November
▼ + stars: | 2024-10-24 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Looking ahead to November, Oppenheimer has updated its top stock ideas list, which features additions such as CarMax , Mastercard and Atlassian . He has an outperform rating on the stock, and his price target implies nearly 26% upside from Wednesday's close. Analyst Ittai Kidron has an outperform rating on the stock, and his $230 target reflects nearly 22% upside, as of Wednesday's close. That implies more than 15% upside from Wednesday's close. Evercore ISI also added Broadcom to its top chip stock picks ahead of its earnings report later in the year.

Persons: Oppenheimer, Michael Wiederhorn, Cigna, Ittai Kidron, Kidron, Atlassian, Morgan Stanley, Rick Schafer, Schafer, Hock Tan Organizations: Dow Jones, Nasdaq, Mastercard, Dick's Sporting Goods, Bloomberg, Humana, Bloomberg News, Broadcom, ISI

☆ Underestimated the Fed's success and consumer strength with price targets: Oppenheimer's Stoltzfus
▼ + stars: | 2024-10-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailUnderestimated the Fed's success and consumer strength with price targets: Oppenheimer's StoltzfusJohn Stoltzfus, Oppenheimer Asset Management chief investment strategist, joins 'Squawk on the Street' to discuss the strategist's S&P target, why the firm has continued to raise its price targets, and much more.

Persons: John Stoltzfus Organizations: Oppenheimer Asset Management

Some well-known stocks could see big moves on the back of earnings reports this week. CNBC Pro screened to find the stocks that could see the biggest swings in either direction following their earnings releases this week. While the typical analyst polled by LSEG has a hold, they expect a rebound ahead with a price target suggesting shares can bounce more than 13%. Analysts surveyed by LSEG have a buy rating and price target suggesting shares can climb 7%. The average analyst surveyed by LSEG has a buy rating, with a price target suggesting shares should hover around flat for the next year.

Persons: Goldman Sachs, LSEG, Lawson Winder, Oppenheimer's Jason Helfstein Organizations: Columbus Day, United Airlines, CNBC Pro, CNBC, Walgreens, WBA, Walgreens Boots Alliance, Amazon, Dow Jones, Alcoa, Bank of America, Netflix

☆ 12 top stocks to buy with up to 94% upside as markets reach even higher highs in 2025
▼ + stars: | 2024-10-10 | by ( James Faris | ) www.businessinsider.com time to read: +3 min

Here are 12 smaller stocks to buy with up to 94% upside, according to Oppenheimer. Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Although Oppenheimer still prefers large stocks over SMID-caps, the firm sees ample opportunities in that less-loved part of the market. AdvertisementThere are 25 stocks on Oppenheimer's latest SMID-cap list, including 12 new entries that weren't on the second- or third-quarter editions. Those new stocks are below — sorted in alphabetical order by growth theme — along with each one's ticker, market capitalization, sector, growth theme, price target, upside, and commentary.

Persons: Oppenheimer, —, Russell Organizations: Service, Dow Jones Locations: uptrends

☆ Group of smaller stocks is primed for major gains ahead, according to Oppenheimer
▼ + stars: | 2024-10-08 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +3 min

In 2024, the small-cap benchmark Russell 2000 's 8% rise still lags the S & P 500's roughly 19% gain. However, Oppenheimer thinks there is further upside ahead for these names. The stock offers a 5% dividend yield and healthy — albeit "lumpy" — free cash flow growth, the analyst added. CCOI YTD mountain Cogent Communications in 2024 Health-care services stock Chemed is another one of Oppenheimer's favorites. The online sports-betting (OSB) data provider could surge more than 37%, based on the $10 price target Oppenheimer holds on shares.

Persons: Oppenheimer, Russell, Timothy Horan, " Horan, Horan, Chemed, Michael Wiederhorn, Wiederhorn, Jed Kelly, — CNBC's Michael Bloom Organizations: Federal Reserve, Genius Sports, National Football League, Football, Professional

☆ This pharma stock is set to surge 71% thanks to autoimmune disease treatment
▼ + stars: | 2024-10-03 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Oppenheimer thinks a key treatment for a range of autoimmune diseases can be a growth catalyst for Dianthus Therapeutics stock. The firm initiated coverage of the clinical stage biotechnology company with an outperform rating and a $48 per share price target in a Wednesday note. DNTH YTD mountain Dianthus Therapeutics stock. He estimates a more than $20 billion market for this treatment. Investors will be able to gain insight into the treatment's effectiveness in clinical data that will begin to be released in mid-2025, Allred said.

Persons: Oppenheimer, Trevor Allred, Allred, DNTH103 Organizations: Dianthus Therapeutics, Therapeutics, pharma

☆ Nike has to get back on its product innovation game, says Oppenheimer's Brian Nagel
▼ + stars: | 2024-09-27 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNike has to get back on its product innovation game, says Oppenheimer's Brian NagelBrian Nagel, Oppenheimer Senior Analyst, joins 'Closing Bell: Overtime' to discuss his look ahead to Nike next week.

Persons: Oppenheimer's Brian Nagel Brian Nagel, Oppenheimer Organizations: Nike

☆ Oppenheimer's top stock ideas heading into October
▼ + stars: | 2024-09-26 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

This comes after all three major averages recovered from the Aug. 5 global sell-off to close out last month higher. DKNG YTD mountain DKNG, year-to-date Biotechnology stock Viking Therapeutics also made the list. The stock has already surged more than 239% this year as its experimental obesity treatment advances through clinical trials. Telecommunications stock AT & T was another best idea, with its target of $23 implying more than 6% upside. Other names that made the list include Cigna , whose target implies more than 14% upside, and chip giant Broadcom .

Persons: Oppenheimer, Goldman Sachs, Jed Kelly, DKNG, Jay Olson, NASH, Timothy Horan, Horan isn't Organizations: Nasdaq, Dow Jones, Biotechnology, Viking Therapeutics, Telecommunications, AT, JPMorgan, Broadcom

☆ Consumers and earnings have shown remarkable resilience, says Oppenheimer's John Stoltzfus
▼ + stars: | 2024-09-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailConsumers and earnings have shown remarkable resilience, says Oppenheimer's John StoltzfusJohn Stoltzfus, Oppenheimer Asset Management, joins 'Squawk on the Street' to discuss the difference the Fed's recent rate cut makes, if Stoltzfus wants exposure to consumer discretionary sectors, and much more.

Persons: Oppenheimer's John Stoltzfus John Stoltzfus, Stoltzfus Organizations: Oppenheimer Asset Management

☆ Why stocks have a lot more room to rally before hitting a peak, according to a technical analyst
▼ + stars: | 2024-09-23 | by ( Matthew Fox | ) www.businessinsider.com time to read: +4 min

Stock market highs are expected to continue into 2025, according to Oppenheimer's Ari Wald. AdvertisementWald's 6,000 price target for the S&P 500 is based on the median bull market cycle. "The S&P 500 is up 64% over the 23 months between October 2022 and September 2024. And if the current bull market follows the path of the average bull market, stocks could continue to rise through the end of 2025 with the S&P 500 rising to around the 7,000 level. "We view the cycle high for Industrials as confirmation of an intact bull market," Wall said.

Persons: Oppenheimer's Ari Wald, Wald, —, Oppenheimer, Ari Wald, it's, Wall, " Wald Organizations: Service, New York Stock Exchange, ISI Locations: That's

☆ Nike CEO change is a 'step in the right direction,' says Oppenheimer's Brian Nagel
▼ + stars: | 2024-09-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNike CEO change is a 'step in the right direction,' says Oppenheimer's Brian NagelBrian Nagel, Oppenheimer & Co. senior analyst, joins CNBC's 'Power Lunch' to discuss what Nike's leadership change could mean for the company, the path forward for the stock, and more.

Persons: Oppenheimer's Brian Nagel Brian Nagel, Oppenheimer Organizations: Nike, Co

☆ 7 top stocks that can thrive whether Donald Trump or Kamala Harris wins this fall
▼ + stars: | 2024-09-11 | by ( James Faris | ) www.businessinsider.com time to read: +4 min

Read previewLast night's contentious debate between Donald Trump and Kamala Harris brought the looming presidential election fully into the mainstream, even for those who've been trying to block it out. However, strategists at Oppenheimer Research believe those who ignore the election — and the implications that electing Trump or Harris may bring — do so at their peril. Advertisement"This playbook is intended to help investors navigate trading dynamics around the elections," Oppenheimer strategists wrote in a September 9 note. "We expect US foreign policy toward China to become more restrictive over the next four years, irrespective of who wins the election," Oppenheimer strategists wrote. AdvertisementBelow are seven stocks with an outperform rating from Oppenheimer analysts and can survive regardless of whether Republicans or Democrats emerge victorious this fall.

Persons: —, Donald Trump, Kamala Harris, who've, Harris, Steve Eisman, Bernstein, Oppenheimer, Biden Organizations: Service, Investors, Business, Oppenheimer Research, Trump, Republicans Locations: China

☆ July new homes sales numbers are 'almost too good to be true,' says Oppenheimer's Tyler Batory
▼ + stars: | 2024-08-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJuly new homes sales numbers are 'almost too good to be true,' says Oppenheimer's Tyler BatoryTyler Batory, Oppenheimer executive director, joins 'Closing Bell' to discuss the housing market and what's at stake for homebuilder stocks as the Fed signals potential rate cuts.

Persons: Oppenheimer's Tyler Batory Tyler Batory, Oppenheimer

☆ 'Not surprised' by what Fed Chair Powell said today, says Oppenheimer's John Stoltzfus
▼ + stars: | 2024-08-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email'Not surprised' by what Fed Chair Powell said today, says Oppenheimer's John StoltzfusJohn Stoltzfus, Oppenheimer Asset Management, joins 'Fast Money' to talk today's Fed speak, the impact of possible cuts on the markets and more.

Persons: Powell, Oppenheimer's John Stoltzfus John Stoltzfus Organizations: Oppenheimer Asset Management

☆ Oppenheimer's Brian Nagel on Home Depot: The sales weakness is going to persist for a while
▼ + stars: | 2024-08-13 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailOppenheimer's Brian Nagel on Home Depot: The sales weakness is going to persist for a whileBrian Nagel, Oppenheimer & Company senior equity research analyst, joins 'Squawk Box' to break down Home Depot's quarterly earnings results.

Persons: Brian Nagel, Oppenheimer Organizations: Oppenheimer & Company

(This is CNBC Pro's live coverage of Monday's Wall Street chatter as global markets sell off. — Lisa Kailai Han 7:02 a.m.: How long sell-offs typically last Bad news: The current market sell-off may have further to go. — Lisa Kailai Han 6:09 a.m.: Oppenheimer's Stoltzfus: Best to not 'jump to conclusions' Investors need to have a cool head as global markets sell off, according to Oppenheimer's John Stoltzfus. — Fred Imbert 5:51 a.m.: Global markets in an 'aggressive risk-unwind', Vital Knowledge says Fears of a U.S. recession are pressuring global markets, leading investors around the world to sell some of this year's top winners, according to Adam Crisafulli of Vital Knowledge. "Markets are caught in an aggressive risk-unwind as equities plunge around the world, with tech getting hit particularly hard," he wrote in a note Monday.

Persons: Wharton's Siegel, Jeremy Siegel, CNBC's, Siegel, hasn't, it's, … They're, —, Lisa Kailai Han, Tom Lee, Lee, Duncan Toms, Toms, Fred Imbert, Victoria Greene, Greene, It's, Nimrit Kang, — Lisa Kailai Han, Dan Ives, Gene Goldman, Gennadiy Goldberg, Ives, Goldman, Goldberg, Oppenheimer's John Stoltzfus, Evercore, Ed Hyman, Hyman, Adam Crisafulli, Crisafulli Organizations: CNBC, Stock, Nikkei, Dow Jones Industrial, Nasdaq, Wharton, Federal Reserve, Fundstrat Global, HSBC, G Squared, Wealth, NorthStar Asset Management, Street, Wedbush, TD Securities, Federal, NASDAQ, U.S, Fed, Global Locations: U.S, Europe, Japan, China

☆ Wall Street is bullish on stocks for the 2nd half of the year. Here are each firm's exact forecasts.
▼ + stars: | 2024-07-12 | by ( Matthew Fox | ) www.businessinsider.com time to read: +7 min

The most bullish S&P 500 price target is 6,000 from Evercore ISI, which represents a gain of about 7%. While the average year-end S&P 500 price target is 5,429, according to data from Bloomberg, the median year-end price target is 5,600. Yardeni Research: S&P 500 price target of 5,800Yardeni Research raised its year-end S&P 500 price target to 5,800 from 5,400 this week. Goldman Sachs: S&P 500 price target of 5,600Goldman Sachs strategist David Kostin boosted his S&P 500 price target to 5,600 from 5,200 last month. UBS: S&P 500 price target of 5,600UBS raised its S&P 500 price target to 5,600 from 5,400 in May, and that's after the bank raised its price target in February.

Persons: —, Julian Emanuel, Emanuel, they're, Oppenheimer, John Stoltzfus, Stoltzfus, Eric Wallerstein, Wallerstein, Ned Davis, Ed Clissold, Goldman Sachs, David Kostin, Kostin, Jonathan Golub Organizations: Wall, ISI, Service, Bloomberg, CNBC, Security, Yardeni, Research, Federal Reserve, Ned Davis Research, UBS, Chicago, & $ Locations: bearish

☆ Oppenheimer's best small and mid-cap stock ideas to play the market broadening
▼ + stars: | 2024-07-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailOppenheimer's best small and mid-cap stock ideas to play the market broadeningJed Kelly, Managing Director of Equity Research at Oppenheimer, discusses his bull thesis for Genius Sports.

Persons: Jed Kelly Organizations: Equity Research, Oppenheimer, Genius Sports

☆ The best small- and midcap stocks to buy this summer, according to Oppenheimer
▼ + stars: | 2024-07-10 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

With the second half of the year underway, Oppenheimer is highlighting what it calls its top small- and midcap seasonal standout investment ideas. On the basis of price charts alone, Oppenheimer tapped midcap growth stocks as its top rotation idea from a technical perspective. Oppenheimer has a $20 price target on Zeta, implying 18% upside from Tuesday's close. In a note last month, RBC Capital Markets also rated Zeta outperform with a price target of $20. In this area, Oppenheimer likes Viking Therapeutics , reiterating the stock as one of its best ideas.

Persons: Oppenheimer, Russell, Brian Schwartz, Zeta, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Jay Olson, Freshpet Organizations: Oppenheimer, Zeta Global Holdings, Zeta, RBC Capital Markets, Novo Nordisk's, Viking Therapeutics, Therapeutics Locations: Zeta, Novo

Search resuls for: "Oppenheimer's"

25 mentions found